Assessment of dapagliflozin effect on diabetic endothelial dysfunction of brachial artery (ADDENDA-BHS2 trial): rationale, design, and baseline characteristics of a randomized controlled trial.
Riobaldo M R CintraAlexandre A S SoaresIkaro BrederDaniel B MunhozJoaquim BarretoSheila T Kimura-MedorimaPamela CavalcanteRenata ZanchettaJessica Cunha BrederCamila MoreiraVitor W VirginioIsabella BonilhaJose Carlos Lima-JuniorOtavio R Coelho-FilhoVaneza L W WolfGil Guerra-JuniorDaniela C OliveiraRodrigo HaeitmannVicente H R FernandesWilson NadruzFernando R P ChavesCarlos E L ArietaThiago QuinagliaAndrei Carvalho Spositonull nullPublished in: Diabetology & metabolic syndrome (2019)
The ADDENDA-BHS2 trial is an investigator-initiated clinical trial comparing the effect of dapagliflozin versus glibenclamide on several aspects of vascular function in high cardiovascular risk T2DM patients. Besides, a large clinical and biochemical phenotype assessment will be obtained for exploring potential mediations and associations.Trial registration Clinical trial registration: NCT02919345 (September, 2016).